Emerging pharmacotherapies for obesity: A systematic review Pharmacological Reviews CagriSema 2026: Everything You Need to Know About the Next Gen Weight Loss Combination Semaglutide, a glucagon like peptide 1 (GLP 1) receptor agonist, has well established weight loss benefits. Cagrilintide, a long acting analogue of the satiety hormone amylin, has shown promise for weight loss in early trials. The potential benefit PDF) Comparative Efficacy and Safety of Semaglutide, Cagrilintide, and CagriSema for the Treatment of Type 2 Diabetes Mellitus: A Bayesian Network Meta Analysis Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 24 mg for weight management: a randomised, controlled, phase 1b trial The Lancet